Furthermore, Chaudhary et al. [68] presented that MMP-2 and MMP-9 levels increased as the disease progressed, indicating their potential as biomarkers for assessing leukemic burden in AML. The gene discussed is MMP2; the disease is acute myeloid leukemia.